Zai Lab bombs Phase IIa tri­al in atopic der­mati­tis, junks the pro­gram to shift re­sources to the pipeline

Nas­daq dar­ling and Shang­hai hot­shot Zai Lab is ditch­ing one of its late-stage drug pro­grams af­ter bomb­ing a Phase IIa tri­al. The com­pa­ny said Fri­day that its top­i­cal prod­uct ZL-3101 (al­so called Fu­gan) did not clear up eczema.

The drug was test­ed in a dou­ble-blind, ran­dom­ized, and place­bo-con­trolled tri­al with 295 Chi­nese pa­tients with atopic der­mati­tis. Fu­gan was safe and well-tol­er­at­ed, but al­so a bit use­less. The treat­ment showed no dif­fer­ence com­pared to place­bo in the pri­ma­ry end­point: a change in the eczema area and sever­i­ty in­dex score at day 21.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.